Arvinas Reports Positive Phase 1 Data for ARV-102

An update from Arvinas Holding Company ( (ARVN) ) is now available.

Arvinas, Inc., a clinical-stage biotech focused on PROTAC-based targeted protein degradation, reported positive Phase 1 data on March 18, 2026, for ARV-102, an oral LRRK2 degrader designed to cross the blood-brain barrier in Parkinson’s disease patients. The trial showed dose-dependent brain penetration and sustained reductions of LRRK2 and related endolysosomal and neuroinflammatory biomarkers, with ARV-102 generally safe and well tolerated across all tested doses.

In the single-center, randomized, double-blind, placebo-controlled multiple-dose cohort, daily ARV-102 at 20 mg to 80 mg achieved approximately 50% or greater LRRK2 degradation in cerebrospinal fluid by day 14, maintained through day 28, alongside peripheral LRRK2 degradation and biomarker changes consistent with healthy-volunteer data. On the back of these results, which suggest a differentiated biomarker impact versus prior LRRK2 inhibitors, Arvinas plans to extend development of ARV-102 into additional LRRK2- and lysosomal dysfunction–associated neurodegenerative diseases, including a Phase 1b study in progressive supranuclear palsy expected to begin in the second quarter of 2026 while it assesses further paths in Parkinson’s disease.

The most recent analyst rating on (ARVN) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Arvinas Holding Company stock, see the ARVN Stock Forecast page.

Spark’s Take on ARVN Stock

According to Spark, TipRanks’ AI Analyst, ARVN is a Neutral.

ARVN scores middling primarily due to weak financial performance (ongoing losses, significant cash burn, and 2025 gross profit volatility) despite low leverage. The earnings call adds support with credible 2026 clinical catalysts and cost control, but the steep cash decline and revenue drop elevate risk. Technicals are neutral-to-soft, and valuation is constrained by negative earnings and no dividend support.

To see Spark’s full report on ARVN stock, click here.

More about Arvinas Holding Company

Arvinas, Inc. is a clinical-stage biotechnology company specializing in targeted protein degradation therapies built on its PROTAC platform, aiming to harness the body’s protein disposal system to remove disease-causing proteins. The New Haven, Conn.-based company is advancing a pipeline that includes ARV-102 for neurodegenerative diseases, oncology candidates such as ARV-806 and ARV-393, a muscle-focused program ARV-027, and vepdegestrant for ER+/HER2- breast cancer.

Average Trading Volume: 783,658

Technical Sentiment Signal: Sell

Current Market Cap: $768.2M

Learn more about ARVN stock on TipRanks’ Stock Analysis page.